Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Short Title: S1922

Enrollment Status: Recruiting

NCT #: NCT04205968

Specialty Area: Oncology

Conditions Studied: Biliary Tract Cancer; Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Gallbladder Cancer; Ampullary Cancer

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To find out if combining cabozantinib with nivolumab improves outcomes for patients with advanced biliary tract cancers.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with advanced or metastatic biliary tract cancer (BTC)
Must have received one prior line of systemic therapy
Must be healthy enough to receive immunotherapy and targeted chemotherapy
No prior treatment with cabozantinib or immune checkpoint inhibitors

What's Involved

Participation in the study will include:

Intravenous (IV) infusion of nivolumab
Oral tablets of cabozantinib taken daily
CT/MRI scans to monitor response to treatment
Blood and urine samples to check your health and how the treatment is working
Questionnaires

Principal Investigator

Harry Menon, DO

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT04205968

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews